Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

UFluA · UFluA 60, UFluA 20

Vaccine · Immune activation · developed by Emergent BioSolutions

Phase 1 Most advanced trial (none active)
EBS Developer
1 Registered trials

What is UFluA?

UFluA is a vaccine candidate studied for the prevention of human influenza A infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
UFluA 60, UFluA 20
Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Emergent BioSolutions (EBS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05155319 Phase 1 Human Influenza Completed EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Human Influenza

More from Emergent BioSolutions

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3

Follow EBS, the company behind UFluA

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.